HK Stock Market Move | QINGSONG HEALTH (02661) rose more than 20% in morning trading, releasing evidence-based medical AI glasses system "Zhengjing", promoting high-quality medical capabilities to sink to the grassroots level.

QINGSONG HEALTH (02661) rose more than 20% in the morning session, up 17.2% as of press time, at HK$14.62, with a turnover of HK$1.14 billion. On the news front, QINGSONG HEALTH recently officially launched the world's first evidence-based medical AI glasses system - "Zheng Jing" at the Asia Consumer Electronics Technology Exhibition (CES Asia). "Zheng Jing" uses AI glasses as the first entry point and QINGSONG HEALTH's self-developed evidence-based medical intelligent body "Zheng Yuanfang" as the core capability, focusing on real medical scenarios such as diagnosis, ward rounds, visits, consultations, and follow-ups to build a clinical auxiliary system. For the Chinese medical environment, the value of "Zheng Jing" lies not only in the introduction of an AI medical hardware system, but also in promoting high-quality medical capabilities to grassroots levels. It is worth mentioning that, unlike traditional voice recording tools or general large-scale model applications, the core capability of "Zheng Jing" comes from the evidence-based medical intelligent body "Zhenyuan Fang". "Zheng Yuanfang" is built based on authoritative medical literature, clinical guidelines, and professional knowledge systems, providing doctors with medical support that is traceable and traceable evidence chain, covering Chinese authoritative medical guidelines, and is more suitable for the clinical environment in China and the actual needs of doctors. Through "Zheng Jing," "Zheng Yuanfang" can no longer stay on the desktop or in dialogue boxes, but can enter mobile work scenarios such as doctors' ward rounds, visits, consultations, and provide assistance at the first scene where clinical information is generated.